The translocation t(14;16) in multiple myeloma (MM) is considered as a high-risk cytogenetic abnormality. This translocation results in the overexpression of a gene called MAF (musculoaponeurotic fibrosarcoma), which can lead to aggressive tumor growth.
Patients with MM who have this translocation typically have a poorer prognosis than those without it. This translocation is associated with advanced disease stage, increased incidence of extramedullary disease, and shorter survival times.
Patients with t(14;16) also seem to be less responsive to standard chemotherapy regimens, although some studies suggest that novel agents such as proteasome inhibitors and immunomodulatory drugs may offer some benefit.
However, the overall risk can depend on various factors, including the presence of other cytogenetic abnormalities, the patient's overall health, response to treatment, and more. Therefore, it's important for each patient's situation to be evaluated individually.
Current research is focused on better understanding this translocation and its implications, as well as developing more effective treatments for patients with this high-risk form of MM. |
求助已关闭
30